![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations
|
|
|
Reported by Jules Levin
19th International Workshop on ClinicalPharmacologyof AntiviralTherapy, 22 -24 May2018, Baltimore, Maryland, USA
Calcagno A, CusatoJ, ScarvaglieriE, AudagnottoS, De Nicoḷ A, Imperiale D, MighettoL, D'AvolioA, Di PerriG, Bonora S.
Defining total-body AIDS-virus burden with implications for curative strategies
![AASDL1](../images%20/053118/053118-6/AASDL1.gif)
![AASDL2](../images%20/053118/053118-6/AASDL2.gif)
![AASDL3](../images%20/053118/053118-6/AASDL3.gif)
![AASDL4](../images%20/053118/053118-6/AASDL4.gif)
![AASDL5](../images%20/053118/053118-6/AASDL5.gif)
![AASDL6](../images%20/053118/053118-6/AASDL6.gif)
![AASDL7](../images%20/053118/053118-6/AASDL7.gif)
![AASDL8](../images%20/053118/053118-6/AASDL8.gif)
![AASDL9](../images%20/053118/053118-6/AASDL9.gif)
![AASDL10](../images%20/053118/053118-6/AASDL10.gif)
![AASDL11](../images%20/053118/053118-6/AASDL11.gif)
![AASDL12](../images%20/053118/053118-6/AASDL12.gif)
![AASDL13](../images%20/053118/053118-6/AASDL13.gif)
![AASDL14](../images%20/053118/053118-6/AASDL14.gif)
![AASDL15](../images%20/053118/053118-6/AASDL15.gif)
![AASDL16](../images%20/053118/053118-6/AASDL16.gif)
![AASDL17](../images%20/053118/053118-6/AASDL17.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|